Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Sees Significant Growth in Short Interest

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 7,300 shares, a growth of 55.3% from the February 13th total of 4,700 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 440,100 shares, the days-to-cover ratio is presently 0.0 days.

Enzon Pharmaceuticals Price Performance

Shares of ENZN traded up $0.00 on Friday, hitting $0.10. The company’s stock had a trading volume of 1,681 shares, compared to its average volume of 93,211. The company has a market capitalization of $7.50 million, a PE ratio of 10.11 and a beta of 0.26. Enzon Pharmaceuticals has a fifty-two week low of $0.06 and a fifty-two week high of $0.24. The company has a 50 day moving average price of $0.13 and a 200 day moving average price of $0.12.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.